Christophe Plisson, Ph.D. | Head of Preclinical Services, Invicro
The continued growth in PET imaging has similarly spurred significant interest in expanding radiosynthetic methodologies to access novel imaging agents. Although substantial advances have been achieved in expanding the radiochemist toolbox in recent years, radiolabeling success still remains an investigative exercise to properly match the substrate to the labeling methodology and unique environment that short-lived isotopes demand. Herein, we describe the key considerations when working with two of the most common PET isotopes, carbon-11 and fluorine-18, to minimize these development obstacles and ensure the designed substrate is best suited for labeling success.
In this webinar, the presenters will discuss:
How the design of the labeling substrate is the most crucial aspect to ensure radiolabeling success
The low concentrations, cyclotron-produced, short-half lives and radiation hazard of isotopes are unique aspects that demand a different chemical approach
Radiolabeling design and process should not only focus on the isotopic bond formation but the molecule in its entirety
Vince Carroll, PH.D.
Senior Director, Chemistry, Invicro
Dr. Carroll brings significant experience to Invicro in PET and SPECT diagnostic tool development, from synthetic discovery through early phase preclinical work and into clinical application. During his time at Invicro, he has led over 20 successful IND submissions, ranging from small-to-large biomolecules for various neuro and oncology applications. In his current role, Dr. Carroll oversees preclinical translation efforts in support of first-in-human studies and the GMP manufacturing and quality control of FDA approved radiotracers supporting early phase clinical trials.
Christophe Plisson, PH.D.
Head of Preclinical Services, Invicro
Dr. Plisson has been working at Invicro since 2011 and currently holds a position as Head of Preclinical Services, overseeing R&D PET chemistry and preclinical PET imaging activities.
Dr. Plisson started to work in the field of PET imaging at the University of Emory in 2001 and joined GlaxoSmithKline in 2004, where he worked on PET tool compound discovery and PET chemistry to support across the drug development portfolio.
Dr. Plisson also held an honorary position of assistant professor at the University of Columbia and holds a Ph.D. in organic chemistry from the University of Orleans, France.
